Stocks · Healthcare · Medical - Devices
PROCEPT BioRobotics Corporation PRCT
$17.16 +0.82% Close, Oct 2, 2026 · NASDAQ · Market cap $976.7M
Weak trend
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Over the past year the stock returned -50.6%, behind the S&P 500 by 65.7 percentage points.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
- The stock is 54% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth70Positive
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 31%
- Revenue growth, 3-year CAGRTop 11%
- Revenue growth accelerationBottom 22%
Quality20Very weak
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 44%
- Gross marginBottom 49%
- Operating marginBottom 38%
- Accruals (lower is better)Bottom 15%
- Interest coverBottom 20%
Value46Neutral
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 43%
- Free-cash-flow yieldBottom 32%
- EBITDA / enterprise valueBottom 37%
- Sales / enterprise valueTop 31%
Momentum9Very weak
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 12%
- 6-month returnBottom 15%
- 1-year return vs S&P 500Bottom 10%
- Distance from 52-week highBottom 23%
- Trend checklist (0–4)Bottom 14%
Revisions4Very weak
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 23%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 21%
- Upside to consensus price targetBottom 35%
Stability49Neutral
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 42%
- Maximum drawdown, 3 yearsBottom 27%
- Beta vs S&P 500 (lower is better)Top 26%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 29.3% | 22.7% | ↓ |
| Gross margin | 63.6% | 63.7% | ↑ |
| Operating margin | -33.4% | -33.9% | ↓ |
| FCF margin | -32.5% | -37.3% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 22.7% | 29.3% | ↓ | Top 31% |
| Gross margin | 63.7% | 63.6% | ↑ | Bottom 49% |
| Operating margin | -33.9% | -33.4% | ↓ | Bottom 38% |
| Net margin | -32.5% | -30.6% | ↓ | — |
| Free-cash-flow margin | -37.3% | -32.5% | ↓ | — |
| Return on invested capital | -27.3% | — | Bottom 44% | |
| Revenue growth, 3-year CAGR | 60.1% | — | Top 11% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 0.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 19.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +10.5 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -32.9×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.96%
- Shareholder yield
- -0.96%
- Share count change, 1 year
- +1.9%
- Share count change, 3-year CAGR
- +7.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -15.5%
- Average 2-day reaction, last 8
- +1.9%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $22.13
- Target vs current price
- +29.0%
- Analysts with a rating
- 16
- Share rating Buy or Strong Buy
- 56%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 4, 2026 | -1.8% | -0.5% | +18.1% | +15.3% | — |
| Apr 29, 2026 | -1.8% | -5.7% | +9.3% | +14.9% | -27.5% |
| Feb 25, 2026 | -65.6% | +2.1% | -3.7% | -7.9% | +3.1% |
| Nov 4, 2025 | +7.3% | +1.5% | -10.3% | -14.4% | -16.1% |
| Aug 6, 2025 | +14.6% | -5.0% | -19.8% | -21.4% | -25.3% |
| Apr 24, 2025 | +8.2% | -5.6% | -3.1% | +1.7% | +2.4% |
| Feb 25, 2025 | -2.9% | -3.7% | -7.0% | -6.5% | -9.2% |
| Oct 28, 2024 | +16.7% | +32.3% | +34.2% | +36.1% | +6.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.47 | -$0.46 | -1.8% | $94.5M |
| Apr 29, 2026 | -$0.56 | -$0.55 | -1.8% | $83.1M |
| Feb 25, 2026 | -$0.53 | -$0.32 | -65.6% | $76.4M |
| Nov 4, 2025 | -$0.38 | -$0.41 | +7.3% | $83.3M |
| Aug 6, 2025 | -$0.35 | -$0.41 | +14.6% | $79.2M |
| Apr 24, 2025 | -$0.45 | -$0.49 | +8.2% | $69.2M |
| Feb 25, 2025 | -$0.35 | -$0.34 | -2.9% | $68.2M |
| Oct 28, 2024 | -$0.40 | -$0.48 | +16.7% | $58.4M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 2.45× | — | — | Top 31% |
| Free-cash-flow yield | -12.90% | — | — | Bottom 32% |
| Earnings yield | -11.31% | — | — | Bottom 43% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -2.6%
- 200-day average slope (20 days)
- -5.1%
- Distance from 50-day average
- -13.5%
- Distance from 200-day average
- -30.6%
- RSI (14)
- 36.3
- Relative volume
- 0.87×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 59.8%
- Volatility vs own 5-year history
- 49th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.67
- Correlation with S&P 500
- 0.18
- Current drawdown from 1-year high
- -53.6%
- Maximum drawdown, 3 years
- -83.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 4, 2024 | Jul 24, 2026 | -83.2% | 408 days | Not yet recovered |
| Oct 13, 2021 | Jan 27, 2022 | -63.5% | 73 days | 154 days (Sep 8, 2022) |
| Sep 9, 2022 | Oct 30, 2023 | -50.9% | 286 days | 81 days (Feb 27, 2024) |
| Sep 20, 2024 | Oct 24, 2024 | -21.4% | 24 days | 2 days (Oct 28, 2024) |
| Jul 17, 2024 | Aug 5, 2024 | -20.9% | 13 days | 12 days (Aug 21, 2024) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $976.7M
- EPS, diluted (TTM)
- -$1.94
- Revenue (TTM)
- $337.3M
- 52-week range
- $16.67 – $38.11
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $34.5M | $75.0M | $136.2M | $224.5M | $308.1M |
| Gross profit | $15.9M | $37.1M | $71.0M | $137.1M | $196.2M |
| Operating income | -$54.2M | -$80.7M | -$109.2M | -$96.6M | -$103.9M |
| Net income | -$59.9M | -$87.2M | -$105.9M | -$91.4M | -$95.6M |
| EPS (diluted) | -$1.37 | -$1.96 | -$2.24 | -$1.75 | -$1.72 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $58.4M | $68.2M | $69.2M | $79.2M | $83.3M | $76.4M | $83.1M | $94.5M |
| Net income | -$21.0M | -$18.9M | -$24.7M | -$19.6M | -$21.4M | -$29.8M | -$31.6M | -$26.9M |
| EPS (diluted) | -$0.40 | -$0.35 | -$0.45 | -$0.35 | -$0.38 | -$0.53 | -$0.56 | -$0.47 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$57.3M | -$80.4M | -$108.0M | -$99.2M | -$49.0M |
| Capital expenditure | -$592,000 | -$2.7M | -$25.2M | -$4.4M | -$9.4M |
| Free cash flow | -$57.9M | -$83.0M | -$133.2M | -$103.6M | -$58.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $172.4M | $0 | $161.7M | $164.5M | $11.2M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $227.9M
- Total assets
- $479.4M
- Total liabilities
- $139.3M
- Total debt
- $77.5M
- Net debt
- -$150.4M
- Shareholders’ equity
- $340.1M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 7,440,176
- Days to cover
- 5.56
- Change vs previous report
- +2.6%
FINRA short interest, settlement date Sep 15, 2026.